Epigenetic modulation by small molecule compounds for neurodegenerative disorders

&NA; The accumulation of somatic and genetic mutations which altered the structure and coding information of the DNA are the major cause of neurological disorders. However, our recent understanding of molecular mechanisms of ‘epigenetic’ phenomenon reveals that the modifications of chromatin play a significant role in the development and severity of neurological disorders. These epigenetic processes are dynamic and reversible as compared to genetic ablations which are stable and irreversible. Therefore, targeting these epigenetic processes through small molecule modulators are of great therapeutic potential. To date, large number of small molecule modulators have been discovered which are capable of altering the brain pathology by targeting epigenetic enzymes. In this review, we shall put forward the key studies supporting the role of altered epigenetic processes in neurological disorders with especial emphasis on neurodegenerative disorders. A few small molecule modulators which have been shown to possess promising results in the animal model system of neurological disorders will also be discussed with future perspectives. Graphical abstract Figure. No caption available.

• Publication year

  2018

• Venue

  Pharmacological Research

• Publication date

  2018-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.phrs.2018.04.014PMID 29684672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The long noncoding RNA HOTAIR promotes Parkinson’s disease by upregulating LRRK2 expression

  2017cited by this paper
• DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge

  2017cited by this paper
• The emerging field of epigenetics in neurodegeneration and neuroprotection

  2017cited by this paper
• Regulatory Roles of Long Non-Coding RNAs in the Central Nervous System and Associated Neurodegenerative Diseases

  2017cited by this paper
• Histone Lysine Methylation and Neurodevelopmental Disorders

  2017cited by this paper
• Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

  2017cited by this paper
• Pharmacokinetics of the Experimental Non‐Nucleosidic DNA Methyl Transferase Inhibitor N‐Phthalyl‐l‐Tryptophan (RG 108) in Rats

  2016cited by this paper
• Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms

  2016cited by this paper
• Small Molecule Inhibitors of Protein Arginine Methyltransferases

  2016cited by this paper
• Histone deacetylase inhibitor SAHA attenuates post-seizure hippocampal microglia TLR4/MYD88 signaling and inhibits TLR4 gene expression via histone acetylation

  2016cited by this paper
• Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity

  2016cited by this paper
• A ketogenic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome

  2016cited by this paper
• Altered Long Noncoding RNA Expression Precedes the Course of Parkinson’s Disease—a Preliminary Report

  2016cited by this paper
• Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2.

  2016cited by this paper
• HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity

  2016cited by this paper
• DNA methylation in Huntington's disease: Implications for transgenerational effects.

  2016cited by this paper
• Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex.

  2016cited by this paper
• The Role of Long Noncoding RNAs in Neurodegenerative Diseases

  2016cited by this paper
• Epigenetic Changes in Neurodegenerative Diseases

  2016cited by this paper
• Circulating microRNAs in Huntington's disease: Emerging mediators in metabolic impairment.

  2016cited by this paper
• Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

  2016cited by this paper
• The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice

  2016cited by this paper
• DNA methylation profiling in human Huntington's disease brain.

  2016cited by this paper
• The roles of non-coding RNAs in Parkinson’s disease

  2016cited by this paper
• Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.

  2016cited by this paper
• A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

  2015cited by this paper
• Mechanisms of Long Non-coding RNAs in Mammalian Nervous System Development, Plasticity, Disease, and Evolution.

  2015cited by this paper
• Identification and expression patterns of novel long non-coding RNAs in neural progenitors of the developing mammalian cortex

  2015cited by this paper
• Epigenetic mechanisms in neurological and neurodegenerative diseases

  2015cited by this paper
• Molecular and Functional Characterization of Bacopa monniera: A Retrospective Review

  2015cited by this paper
• Regulation of Histone Acetylation by Autophagy in Parkinson Disease*

  2015cited by this paper
• Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells' differentiation in vitro and in neurochemical models of Parkinson's disease

  2015cited by this paper
• Use of Epigenetic Drugs in Disease: An Overview

  2014cited by this paper
• MicroRNAs and synaptic plasticity—a mutual relationship

  2014cited by this paper
• SnapShot: histone modifications.

  2014cited by this paper
• Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

  2014cited by this paper
• Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013)

  2014cited by this paper
• Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome

  2014cited by this paper
• Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice.

  2014cited by this paper
• Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1-AS expression

  2014cited by this paper
• Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability

  2014cited by this paper
• A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

  2014cited by this paper
• Naphthoquinone-mediated Inhibition of Lysine Acetyltransferase KAT3B/p300, Basis for Non-toxic Inhibitor Synthesis*

  2014cited by this paper
• The promise and perils of HDAC inhibitors in neurodegeneration

  2014cited by this paper
• Extensive changes in DNA methylation are associated with expression of mutant huntingtin

  2013cited by this paper
• A Novel Activator of CBP/p300 Acetyltransferases Promotes Neurogenesis and Extends Memory Duration in Adult Mice

  2013cited by this paper
• Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients.

  2013cited by this paper
• DNA methylation, a hand behind neurodegenerative diseases

  2013cited by this paper
• Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases.

  2013cited by this paper
• Epigenetics, Autism Spectrum, and Neurodevelopmental Disorders

  2013cited by this paper
• Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities

  2013cited by this paper
• Tet1 is critical for neuronal activity-regulated gene expression and memory extinction.

  2013cited by this paper
• A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests

  2013cited by this paper
• Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease

  2013cited by this paper
• Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor.

  2013cited by this paper
• The Vast, Conserved Mammalian lincRNome

  2013cited by this paper
• Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases

  2013cited by this paper
• Increased 5-Methylcytosine and Decreased 5-Hydroxymethylcytosine Levels are Associated with Reduced Striatal A2AR Levels in Huntington’s Disease

  2013cited by this paper
• Spinal muscular atrophy: an update on therapeutic progress.

  2013cited by this paper
• Transcriptome sequencing during mouse brain development identifies long non‐coding RNAs functionally involved in neurogenic commitment

  2013cited by this paper
• Long non-coding RNAs in Huntington's disease neurodegeneration.

  2012cited by this paper
• GENCODE: The reference human genome annotation for The ENCODE Project

  2012cited by this paper
• Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines.

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat

  2012cited by this paper
• The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression

  2012cited by this paper
• MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction.

  2012cited by this paper
• Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients

  2012cited by this paper
• MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice.

  2012cited by this paper
• Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

  2012cited by this paper
• MicroRNAs in learning, memory, and neurological diseases.

  2012cited by this paper
• 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site.

  2012cited by this paper
• Epigenetics-Based Therapeutics for Neurodegenerative Disorders

  2012cited by this paper
• Genome-Wide DNA Methylation Differences Between Late-Onset Alzheimer's Disease and Cognitively Normal Controls in Human Frontal Cortex

  2012cited by this paper
• In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs

  2011cited by this paper
• Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

  2011cited by this paper
• Sodium Butyrate Improves Memory Function in an Alzheimer's Disease Mouse Model When Administered at an Advanced Stage of Disease Progression

  2011cited by this paper
• MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function.

  2011cited by this paper
• Identification of Novel GDNF Isoforms and cis-Antisense GDNFOS Gene and Their Regulation in Human Middle Temporal Gyrus of Alzheimer Disease*

  2011cited by this paper
• Epigenetic Regulation of Motor Neuron Cell Death through DNA Methylation

  2011cited by this paper
• Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases.

  2011cited by this paper
• Subregion-specific p300 conditional knock-out mice exhibit long-term memory impairments.

  2011cited by this paper
• SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease

  2011cited by this paper
• Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.

  2011cited by this paper
• MicroRNA function in the nervous system.

  2011cited by this paper
• Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal Neurogenesis

  2011cited by this paper
• Faculty Opinions recommendation of lincRNAs act in the circuitry controlling pluripotency and differentiation.

  2011cited by this paper
• Cortical DNA methylation maintains remote memory

  2010cited by this paper
• Neuroprotective effect of luteolin on amyloid β protein (25–35)‐induced toxicity in cultured rat cortical neurons

  2010cited by this paper
• Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model.

  2010cited by this paper
• Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons

  2010cited by this paper
• Histone Deacetylases Suppress CGG Repeat–Induced Neurodegeneration Via Transcriptional Silencing in Models of Fragile X Tremor Ataxia Syndrome

  2010cited by this paper
• Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.

  2010cited by this paper
• Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.

  2010cited by this paper
• Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

  2010cited by this paper
• The Basics of Brain Development

  2010cited by this paper
• Discovery and mechanistic study of a class of protein arginine methylation inhibitors.

  2010cited by this paper
• Epigenetic alterations in aging.

  2010cited by this paper
• Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases.

  2010cited by this paper
• MicroRNA-101 Regulates Amyloid Precursor Protein Expression in Hippocampal Neurons*

  2010cited by this paper

• Landscape of Protein Post-Translational Modifications in Age-Related Neurodegenerative Disorders: Implications in Protein Aggregation, Altered Cellular Processes, and Therapeutics.

  2026cites this paper
• Electromechanically induced membrane restructuring enables learning and memory

  2025cites this paper
• Exploration of the Therapeutic Potential of the Epigenetic Modulator Decitabine on 6-OHDA-Induced Experimental Models of Parkinson's Disease.

  2025cites this paper
• Suppression of KDM5C mitigates the symptoms of Alzheimer's disease by up-regulating BDNF expression.

  2025cites this paper
• Epigenetic modulation rescues neurodevelopmental deficits in Syngap1+/− mice

  2025cites this paper
• Global DNA methylation is not elevated in blood samples from Machado-Joseph disease mutation carriers

  2024cites this paper
• Epigenetic Modulation to perturb the SYNGAP1 Intellectual Disability (ID) that ameliorates synaptic and behavioural deficits

  2024cites this paper
• Oral Administration of a Specific p300/CBP Lysine Acetyltransferase Activator Induces Synaptic Plasticity and Repairs Spinal Cord Injury.

  2024cites this paper
• Neuroprotective potential of Epigenetic modulators, its regulation and therapeutic approaches for the management of Parkinson's disease.

  2024cites this paper
• Epigenetic events influencing the biological clock: Panacea for neurodegeneration

  2024cites this paper
• p300/CBP KATs Are Critical for Maturation and Differentiation of Adult Neural Progenitors.

  2024cites this paper
• A novel dual-epigenetic inhibitor enhances recombinant monoclonal antibody expression in CHO cells

  2024cites this paper
• Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets

  2023cites this paper
• Oral Administration of a specific p300/CBP Lysine Acetyltransferase Activator Induces Synaptic Plasticity and Repairing Spinal Cord Injury

  2023cites this paper
• S100A8 and S100A12 Proteins as Biomarkers of High Disease Activity in Patients with Rheumatoid Arthritis That Can Be Regulated by Epigenetic Drugs

  2022cites this paper
• Glucose derived carbon nanosphere (CSP) conjugated TTK21, an activator of the histone acetyltransferases CBP/p300, ameliorates amyloid‐beta 1–42 induced deficits in plasticity and associativity in hippocampal CA1 pyramidal neurons

  2022cites this paper
• Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System

  2022cites this paper
• A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity

  2021cites this paper
• Small molecule epigenetic modulators for enhancing recombinant antibody production in CHO cell cultures

  2021cites this paper
• Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model

  2021cites this paper
• Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in perinatal Δ9-tetrahydrocannabinol occurs in schizophrenia: analyses in patients and in animal model of the disease.

  2020cites this paper
• Advances in Nutritional Epigenetics—A Fresh Perspective for an Old Idea. Lessons Learned, Limitations, and Future Directions

  2020cites this paper
• Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid

  2020cites this paper
• Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules

  2019cites this paper
• Correction of Niemann-Pick type C1 disease with the histone deacetylase inhibitor valproic acid

  2019cites this paper
• Pharmacological Reactivation of the Silenced FMR1 Gene as a Targeted Therapeutic Approach for Fragile X Syndrome

  2019cites this paper
• Effects of histone acetyltransferase inhibitors on l-DOPA-induced dyskinesia in a murine model of Parkinson’s disease

  2018cites this paper